Detectable vesicular stomatitis virus (VSV)–specific humoral and cellular immune responses following VSV–Ebola virus vaccination in humans
- Poetsch, JH
- Dahlke, C
- Zinser, ME
- Kasonta, R
- Lunemann, S
- Rechtien, A
- Ly, ML
- Stubbe, HC
- Krähling, V
- Biedenkopf, N
- Eickmann, M
- Fehling, SK
- Olearo, F
- Strecker, T
- Sharma, P
- Lang, KS
- Lohse, AW
- Schmiedel, S
- Becker, S
- VEBCON (VSV-Ebola Consortium)
- Addo, MM
- Bejon, P
Publication date
November 2018
DOI Publisher
Oxford University Press (OUP) Journal
The Journal of Infectious DiseasesAbstract
In response to the Ebola virus (EBOV) crisis 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested. A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV-vector are available. Within the scope of a Phase I study, we performed a comprehensive longitudinal analysis of humoral and cellular immune responses to internal VSV-proteins following VSV-EBOV immunization. While no pre-existing immunity to the vector was observed, up to 1/3 of subjects showed VSV-specific CTL-responses and antibodies
Add to ORKG